Araştırma Makalesi

Investigation of apoptotic effects of D-pantothenic acid on PC-3 prostate cancer cells

Cilt: 45 Sayı: 4 27 Aralık 2020
PDF İndir
TR EN

Investigation of apoptotic effects of D-pantothenic acid on PC-3 prostate cancer cells

Abstract

Purpose: The anti-inflammatory and antioxidant properties of D-pantothenic acid have been demonstrated and the effects of dexpentanol on inflammatory pathways and apopototic pathways that trigger cell death are of interest. Apoptotic pathways are important in resistance to chemotherapeutics in cancer diseases and in cancer development. Therefore, we planned how treatment of PC-3 human prostate cancer cells with dexpanthenol will affect the levels and activities of apoptotic and inflammation mediators. For this purpose, human prostate cancer cell culture was performed. Materials and Methods: The human prostate cancer cells were treated with dexpentanaol then protein levels and activities of inflammatory and apoptotic pathway mediators such as gadd153, AIF, grp78, bax and bcl-2 in the cells were analyzed by ELISA. Results: The results of our study showed that, D-pantothenic acid did not statisticaly decreased the leves of bax, bcl-2 and grp78 protein expression in PC-3 prostate cancer cells. The effect of D-pantothenic acid on gadd153 and AIF proteins in PC-3 cells was increased but this increased level did not statisticaly significant. Conclusion: Recent studies have demonstrated the potential benefits of anti-inflammatory drugs. Our study showed that D-pantothenic acid had no significant effect on the growth of PC-3 cells and has no significant effect on intracellular apoptotic pathways.

Kaynakça

  1. 1. Aydın S, Boz MY. Türkiye’de üriner sistem kanserlerinin görülme sıklığında hızlı değişme. Turk Urol Derg. 2015;41(4):215–20.
  2. 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics, 2008. CA Cancer J Clin [Internet]. 2008;58(2):71–96.
  3. 3. Stephenson RA. Prostate cancer overdiagnosis and over treatment.Analysis of US mortality and SEER incidence. Trends in thePSA and pre-PSA eras. In Klein EA (ed): Management of ProstateCancer, 2 nd ed. Totowa, NJ, Humana Pres. 2004:3-13.
  4. 4. Anderson J. Treatment of prostate cancer-The role of primaryhormonal therapy. EAU Update series. 2003:1;32-9
  5. 5. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002:52;154-79.
  6. 6. Daskivich TJ, Oh WK. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol. 2006:16;173-8.
  7. 7. Abrahamsson P. Revalutions in the management of hormone refractory prostate cancer. Eur Urol Suppl 2003:2;1-2.
  8. 8. Gleave M, Kelly WK. High-risk localized prostate cancer: acase for early chemotherapy. J Clin Oncol. 2005:23;8186-91.
  9. 9. Peppa M, Uribarri J., Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works Clin. Diabetes, 21 (4) (2003), pp. 186--187
  10. 10. Bucciarelli L.G., Wendt T., Rong L., et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease Cell Mol. Life Sci., 59 (7) (2002), pp. 1117—1128

Kaynak Göster

MLA
Alizade, Ares, ve Gülüzar Özbolat. “Investigation of apoptotic effects of D-pantothenic acid on PC-3 prostate cancer cells”. Cukurova Medical Journal, c. 45, sy 4, Aralık 2020, ss. 1499-04, doi:10.17826/cumj.736494.